Company news

Adial Pharmaceuticals, Inc (NASDAQ:ADIL) news

Adial Pharmaceuticals, Inc news releases on 6ix. Latest, Aug 7, 2024: Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04…

Adial Pharmaceuticals, Inc (NASDAQ:ADIL) news

Press releases — page 2

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float

Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings

Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business

Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Schedules Business Update Conference Call

Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic Pain

Adial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative Colitis

Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer

Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder

Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH

Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders

Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals Announces Closing of $10 Million Financing

Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma

Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04

Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share

Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer